Bioton Values Glaxo Deal at Up to $600 Million, CEO Tells Puls

Bioton SA of Poland estimates the value of a distribution deal with GlaxoSmithKline Plc at as much as $600 million, Puls Biznesu reported, citing Bioton Chief Executive Officer Slawomir Ziegert.

Bioton announced the 15-year agreement, under which the U.K.-based company will distribute the Polish producer’s insulin in Russia, in a regulatory statement on Dec. 18.

To contact the reporter on this story: Pawel Kozlowski in Warsaw

To contact the editor responsible for this story: Gavin Serkin at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.